Sergio Amadori
About
In The Last Decade
Sergio Amadori
353 papers receiving 15.1k citations
Hit Papers
Peers
Comparison fields: 5 of 143
- Hematology 9.9k
- Molecular Biology 4.1k
- Genetics 3.7k
- Oncology 3.4k
- Public Health, Environmental and Occupational Health 3.0k
Countries citing papers authored by Sergio Amadori
This map shows the geographic impact of Sergio Amadori's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sergio Amadori with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sergio Amadori more than expected).
Fields of papers citing papers by Sergio Amadori
This network shows the impact of papers produced by Sergio Amadori. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sergio Amadori. The network helps show where Sergio Amadori may publish in the future.
Co-authorship network of co-authors of Sergio Amadori
This figure shows the co-authorship network connecting the top 25 collaborators of Sergio Amadori. A scholar is included among the top collaborators of Sergio Amadori based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sergio Amadori. Sergio Amadori is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 57 | |
| 2 | 38 | |
| 3 | 3 | |
| 4 | 185 | |
| 5 | 219 | |
| 6 | Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet breakdown → | 2350 |
| 7 | 1 | |
| 8 | 305 | |
| 9 | 231 | |
| 10 | 102 | |
| 11 | Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. | 141 |
| 12 | 10 | |
| 13 | 19 | |
| 14 | 15 | |
| 15 | Cytogenetic risk group and cytogenetic response predict outcome of patients with poor-risk mds and secondary aml treated with intensive chemotherapy and stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA leukemia groups | 1 |
| 16 | Allogeneic vs autologous stem cell transplantation according to cytogenetic features in AML patients (pts) <= 45 yrs old in first CR: Results of the EORTC-GIMEMA AML-10 trial | 5 |
| 17 | Peripheral stem cells are the preferred source of stem cells for autologous stem cell transplantation (ASCT) of young patients with MDS or AML following MDS: An analysis of the chronic leukaemia working party of the European blood and marrow transplantation group (EBMT) | 4 |
| 18 | The type of anthracycline administered during remission induction and consolidation therapy of AML has an impact on feasibility of subsequent autologous or allogeneic transplantation and induced marrow toxicity: preliminary results of the EORTC-Gimema AML-10 randomized trial. | 5 |
| 19 | AML-M0: a biological and clinical profile | 2 |
| 20 | Allogeneic vs autologous BMT vs intensive chemotherapy in childhood AnLL during first complete remission: AIEOP experience. AIEOP Cooperative Group. | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.